Accent Therapeutics Announces $75 Million Series C Financing to

/PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the

Droia Ventures – Investing in Impact – Life Science

F-star Therapeutics bags $1.5 billion deal with Janssen

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

LinkedIn - Products, Competitors, Financials, Employees, Headquarters Locations

Biotech, Pharmaceutical and Clinical Research News

UNP and Merck & Co to fight tough oncology target

Josh Lang, MBA on LinkedIn: Cambridge based SalioGen Therapeutics raises $115M in Series B funding

How Washington's favorite cancer fighter helps himself - POLITICO

Business & Finance

QurAlis closes $88 million Series B financing

Pharma Industry News and Analysis

Accent Therapeutics - Overview, News & Similar companies

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies -January 24, 2024 at 07:05 am EST

Odyssey Therapeutics Raises $101M in Series C Financing